PP-8-6 Paclitaxel (P) versus doxorublcin (D) as first line chemotherapy (CT) in advanced breast cancer (ABC): A randomized trial with crossover of the EORTC-IDBBC in collaboration with EORTC-ECSG

BackgroundIt is generally accepted that taxanes are among the most active chemotherapy agents in the management of metastatic breast cancer. This is an update of a Cochrane review first published in 2003. ObjectivesThe objective of this review was to compare taxane-containing chemotherapy regimens with regimens not containing a taxane in the management of women with metastatic breast cancer. Search methodsIn this review update, we searched the Cochrane Breast Cancer Group Specialised Register, MEDLINE, EMBASE, the World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP), and ClinicalTrials.gov on 14 February 2013 using keywords such as 'advanced breast cancer' and 'chemotherapy'. We searched reference lists of articles, contacted study authors, and did not apply any language restrictions. Selection criteriaRandomised controlled trials comparing taxane-containing chemotherapy regimens to regimens without taxanes in women with metastatic breast cancer. We included published and unpublished studies. Data collection and analysisTwo review authors independently assessed trial quality and extracted data. We derived hazard ratios (HRs) for overall survival, time to progression, and time to treatment failure where possible, and used a fixed-e ect model for meta-analysis. We represented objective tumour response rates and toxicity as risk ratios (RRs). We extracted quality of life data where present. Main resultsThis review included 28 studies. The updated analysis included 6871 randomised women, while the original review had 3643 women. Of the 28 included studies, we considered 19 studies to be at low risk of bias overall; however, some studies failed to report details on allocation concealment and methods of outcome assessment for those outcomes that are more likely to be influenced by a lack of blinding Taxane-containing regimens for metastatic breast cancer (Review)

show abstract

Taxane-containing regimens for metastatic breast cancer

Ghersi

Willson

Chan

et al. 2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

PP-8-6 Paclitaxel (P) versus doxorublcin (D) as first line chemotherapy (CT) in advanced breast cancer (ABC): A randomized trial with crossover of the EORTC-IDBBC in collaboration with EORTC-ECSG

Cited by 1 publication

References 0 publications

Taxane-containing regimens for metastatic breast cancer

Taxane-containing regimens for metastatic breast cancer

Contact Info

Product

Resources

About